RxDoctor Payments Data

Raymundo Bautista, MD

Internal Medicine · Glendora, CANPI 1912099441

Payments from drug & device makers

$29,564in general payments, 2019–2025

Across 511 payments — averaging $57.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$19K
  • AstraZeneca$3K
  • Amgen$1K
  • Akebia Therapeutics Inc$881
  • Fresenius USA Marketing, Inc.$859
  • OPKO Pharmaceuticals, LLC$632
  • plus $3K from 14 others

What the payments were for

  • Food & beverage$10,770100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,564 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$278,471
Medicare patients
255
Services billed
1,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RayaldeeCalcifediol89$123,002
FarxigaDapagliflozin Propanediol200$114,293
KerendiaFinerenone94$58,762
LokelmaSodium Zirconium Cyclosilicate65$51,368
ProcritEpoetin Alfa55$47,042
DapagliflozinDapagliflozin Propanediol93$46,726
AuryxiaFerric Citrate24$41,388
VeltassaPatiromer Calcium Sorbitex11$8,760
JanuviaSitagliptin Phosphate15$7,579
LipitorAtorvastatin Calcium12$6,326
EliquisApixaban12$6,308
TradjentaLinagliptin12$6,213
Sevelamer Carbonate31$4,945
ClinolipidFat Emulsion/Olive/Soy/Phospho11$2,957
LumiganBimatoprost11$2,644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$3,457$165,661265 claims
OPKO Pharmaceuticals, LLCRayaldee$632$123,00289 claims
BayerKerendia$575$58,76294 claims
Akebia Therapeutics IncAuryxia$881$41,38824 claims
Boehringer IngelheimTradjenta$261$6,21312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Glendora

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →